CMKLR2 and depressive symptom measurement: Inhibitors of Gpr1 have an antidepressant effect and can improve hormone and gene changes caused by depression, suggesting antagonistic peptide of Gpr1 as a potential therapeutic application for hormone-modulated depression in women.